Alemtuzumab ( Campath-1 H ) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma : results of a GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) prospective multicenter trial

1Hematology Department, Ospedale Santa Croce, Cuneo; 2Hematology Department, Università di Udine, Udine; 3Hematology Department, Ospedale Cervello, Palermo, Sicily; 4Hematology Department, Ospedale Regionale Generale, Bolzano; 5Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto; 6Hematology Department, Ospedale Spedali Civili, Brescia; 7Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria; 8Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia; 9Internal Medicine Department, Ospedale Galliera, Genova; 10Hematology Department, Università di Firenze, Firenze; 11Onco-Hematology Department, Ospedale Pascale, Napoli; 12Hematology Department, Università di Palermo, Palermo, Sicily; 13Hematology Department, Ospedale Santa Camillo Forlanini, Roma; 14Medical Statistics Department, Università di Torino, Torino; 15Hemolymphopathology Department, Università di Bologna, Bologna; 16Hematology Department, Università di Torino, Torino, Italy

[1]  Sukjoong Oh,et al.  Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study , 2007, Cancer Chemotherapy and Pharmacology.

[2]  S. Pileri,et al.  Expression of CD52 in peripheral T-cell lymphoma. , 2007, Haematologica.

[3]  A. Horwich,et al.  Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. , 2007, Haematologica.

[4]  M. Czuczman,et al.  Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 , 2007, Leukemia & lymphoma.

[5]  J. Kutok,et al.  Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) , 2006, Clinical Cancer Research.

[6]  O. O’Connor,et al.  Pralatrexate: an emerging new agent with activity in T-cell lymphomas , 2006, Current opinion in oncology.

[7]  T. Barbui,et al.  Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.

[8]  A. Zelenetz,et al.  Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma , 2006, British journal of haematology.

[9]  S. Pileri,et al.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Gisselbrecht,et al.  Managing large cell lymphoma. , 2006, Annals of Oncology.

[11]  C. Dearden.  The role of alemtuzumab in the management of T-cell malignancies. , 2006, Seminars in oncology.

[12]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Christian Buske,et al.  Treatment strategies in follicular lymphomas: current status and future perspectives. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Scott E. Smith,et al.  Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228 , 2005 .

[15]  E. Matutes,et al.  CD52 expression in T-cell large granular lymphocyte leukemia – Implications for treatment with alemtuzumab , 2005, Leukemia & lymphoma.

[16]  K. Savage.  Aggressive peripheral T-cell lymphomas (specified and unspecified types). , 2005, Hematology. American Society of Hematology. Education Program.

[17]  V. Kurup,et al.  Generation of Th1 T Cell Responses Directed to a HLA Class II Restricted Epitope from the Aspergillus f16 Allergen. , 2004 .

[18]  E. Elonen,et al.  Tumours of haematopoietic and lymphoid tissues: general guidelines , 2004 .

[19]  M. Boccadoro,et al.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Erlanson,et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.

[21]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[22]  K. Franssila,et al.  Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey , 2004, Bone Marrow Transplantation.

[23]  M. Introna,et al.  Effect of alemtuzumab on neoplastic B cells. , 2004, Haematologica.

[24]  A. F. Sevilla,et al.  High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Juliusson,et al.  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. , 2003, Blood.

[26]  A. López-Guillermo,et al.  High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. , 2003, Haematologica.

[27]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  D. Catovsky,et al.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.

[29]  M. Munsell,et al.  Impact of high-dose chemotherapy on peripheral T-cell lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Nguyen,et al.  Treatment of refractory T‐cell malignancies using gemcitabine , 2001, British journal of haematology.

[31]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[32]  J. Verhaegen,et al.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.

[33]  A. López-Guillermo,et al.  Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  S. Pileri,et al.  The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. , 1998, Journal of clinical pathology.

[35]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[36]  L. Ginaldi,et al.  Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.

[37]  A. Melnyk,et al.  Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[38]  S. Pileri,et al.  Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  T. Habermann,et al.  Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Gaulard,et al.  Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Fanin,et al.  Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. , 1997, Haematologica.

[42]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[43]  R. Warnke,et al.  Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  F. Berger,et al.  Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .

[45]  Y. C. Chen,et al.  Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately? , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  F. Berger,et al.  T-cell lymphomas: immunologic, histologic, clinical, and therapeutic analysis of 63 cases. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[49]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .